Market Overview

Credit Suisse Believes Top Line Growth Matters More Than Margins For Stericycle

Related SRCL
Earnings Scheduled For February 15, 2017
Jim Cramer Gives His Opinion On Stericycle And Ford
David Rolfe Invests in Tractor Supply, Fastenal (GuruFocus)

In a report published Monday, Credit Suisse analyst Hamzah Mazari reiterated an Outperform rating and $140.00 price target on Stericycle (NASDAQ: SRCL).

In the report, Credit Suisse noted, “We believe that operating leverage given lack of infrastructure pre-PSC deal should lead to much higher than expected earnings power over the next 12-16 months. Recall that SRCL can run StrongPak through PSC infrastructure and cut out third party treatment/disposal costs (i.e. had 1 Part B facility vs 13 post deal) in addition to better optimizing route density/logistics. Our sense is that 12 cents of 2015 full year EPS accretion is low based on our channel checks and past environmental deals.”

Stericycle closed on Thursday at $119.23.

Latest Ratings for SRCL

Nov 2016Goldman SachsDowngradesNeutralSell
Oct 2016Stifel NicolausUpgradesHoldBuy
Sep 2016BairdMaintainsNeutral

View More Analyst Ratings for SRCL
View the Latest Analyst Ratings

Posted-In: Credit Suisse Hamzah MazariAnalyst Color Reiteration Analyst Ratings


Related Articles (SRCL)

View Comments and Join the Discussion!